acquired
Stage
2017
Founded
1
Investors
About
Versanis Bio was a clinical-stage biopharmaceutical company developing bimagrumab, a monoclonal antibody targeting activin receptor type II to treat obesity and cardiometabolic diseases. The company was acquired by Eli Lilly in July 2023.
Explore Versanis Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.